ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...

XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...

Detailed price information for Lyell Immunopharma Inc (LYEL-Q) from The Globe and Mail including charting and trades.

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

Leo Gordon, MD, provides an overview of current treatment strategies currently driven by NCCN guidelines. Leo Gordon, MD: The NCCN [National Comprehensive Cancer Network] is composed of faculty ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Tattoo ink doesn’t just sit inertly in the skin. New research shows it moves rapidly into the lymphatic system, where it can ...

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene ...